Literature DB >> 18718969

Survival with retinoblastoma in the USA: 1975-2004.

E Broaddus1, A Topham, A D Singh.   

Abstract

BACKGROUND: The purpose of this study was to determine the survival of retinoblastoma in the USA over a 30-year period from 1975 to 2004 using a systematic review of existing databases.
METHODS: Nine hundred and ninety-two cases of retinoblastoma (International Classification of Oncology (ICDO-3) codes C69.2 (retina) and C69.9 (eye, NOS)) were derived from the Surveillance, Epidemiology and End Results (SEER) program database in the USA from 1975 to 2004. All 17 current SEER registries were utilised to allow for optimal patient volume for statistical analysis. Survival rates were calculated by the Kaplan-Meier method and differences evaluated with logrank and Wilcoxon tests. Cause of death was obtained and reviewed for all deceased patients. All retinoblastoma patient records were reviewed for treatments given and occurrence of second malignant neoplasms.
RESULTS: There were a total of 990 distinct patients with retinoblastoma. Almost all cases (99.1%) were reported by the hospitals, and histopathological confirmation was available in 87.7% of cases. Over the period of 30 years (1975-2004), the 5-year observed actuarial survival rate increased from 92.3% (1975-84) to 93.9% (1985-94) to 96.5% (1995-2004). The difference in rates was statistically significant (Wilcoxon = 6.2393, p = 0.0442). The proportion of cases treated with radiotherapy first increased from 20.5% in 1975-9 to 34.6% in 1985-9 and then sharply decreased to 6.5% in 2000-4.
CONCLUSIONS: Over the last 30 years, there has been a gradual improvement in 5-year survival of children with retinoblastoma in the USA.

Entities:  

Mesh:

Year:  2008        PMID: 18718969     DOI: 10.1136/bjo.2008.143842

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  56 in total

1.  High-resolution MRI using orbit surface coils for the evaluation of metastatic risk factors in 143 children with retinoblastoma: Part 1: MRI vs. histopathology.

Authors:  Selma Sirin; Marc Schlamann; Klaus A Metz; Norbert Bornfeld; Bernd Schweiger; Markus Holdt; Petra Temming; Michael M Schuendeln; Sophia L Goericke
Journal:  Neuroradiology       Date:  2015-06-04       Impact factor: 2.804

2.  Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study.

Authors:  Danielle Novetsky Friedman; Eric Lis; Charles A Sklar; Kevin C Oeffinger; Marina Reppucci; Megan Harlan Fleischut; Jasmine H Francis; Brian Marr; David H Abramson; Ira J Dunkel
Journal:  Pediatr Blood Cancer       Date:  2013-11-01       Impact factor: 3.167

Review 3.  Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Authors:  Yu-Hsuan Lin; Brittany E Jewell; Julian Gingold; Linchao Lu; Ruiying Zhao; Lisa L Wang; Dung-Fang Lee
Journal:  Trends Mol Med       Date:  2017-07-20       Impact factor: 11.951

4.  The National Registry of Retinoblastoma in Japan (1983-2014).

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2018-05-30       Impact factor: 2.447

Review 5.  Mitochondrial disorders and the eye.

Authors:  Samantha A Schrier; Marni J Falk
Journal:  Curr Opin Ophthalmol       Date:  2011-09       Impact factor: 3.761

6.  Matrine inhibits the growth of retinoblastoma cells (SO-Rb50) by decreasing proliferation and inducing apoptosis in a mitochondrial pathway.

Authors:  Qingliang Shao; Xiaxia Zhao; Li Yao
Journal:  Mol Biol Rep       Date:  2014-02-11       Impact factor: 2.316

Review 7.  Solid tumor second primary neoplasms: who is at risk, what can we do?

Authors:  Kevin C Oeffinger; Shrujal S Baxi; Danielle Novetsky Friedman; Chaya S Moskowitz
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

Review 8.  Challenging issues in pediatric oncology.

Authors:  Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo
Journal:  Nat Rev Clin Oncol       Date:  2011-06-28       Impact factor: 66.675

9.  Epidemiological trends in 1452 cases of retinoblastoma from the Surveillance, Epidemiology, and End Results (SEER) registry.

Authors:  Michael T Andreoli; Felix Y Chau; Michael J Shapiro; Yannek I Leiderman
Journal:  Can J Ophthalmol       Date:  2017-07-22       Impact factor: 1.882

10.  Second primary tumors in retinoblastoma survivors: a study of 7 Asian Indian patients.

Authors:  Swathi Kaliki; Vijay Anand Reddy Palkonda
Journal:  Int Ophthalmol       Date:  2020-07-31       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.